Zydus Cadila has launched biosimilar of Adalimumab, used for the treatment of auto immune disorders. The drug will be available, at a price much lower than the innovator drug, Humira (Adalimumab) by AbbVie.

The biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name 'Exemptia'. The company has got approval for the product for four areas at present, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis.

"The cost of the innovator product by AbbVie is $1,000 per vial. Our Exemptia will be available at one-fifth of its cost in India. It is the first biosimilar of Adalimumab. This therapy will offer a new lease of life to millions in India who did not have access to it so far. We are happy to offer them hope, freedom from pain and better quality of life through Exemptia," said Mr Sharvil P Patel , deputy managing director, Zydus Cadila in a statement.